Vioxx litigation setbacks
Atlantic City, N.J. state court judge sets aside a November verdict in favor of Merck and ordered a new trial for early next year, drug maker says Aug. 17. Decision comes after the New England Journal of Medicine asked Merck to submit a correction restating results of its Vioxx Gastrointestinal Outcomes Research (VIGOR) in a December Expression of Concern (1"The Pink Sheet" Dec. 12, 2005, p. 9). Jury in Humeston v. Merck had cleared the firm of allegations it failed to properly warn patients of risks associated with the use of rofecoxib. Company says it is currently mulling its legal options, which could include interlocutory appeal. Separately, a New Orleans jury awards $51 mil. in damages to the plaintiff in the second Vioxx federal lawsuit, a verdict the firm says it will challenge...
You may also be interested in...
The New England Journal of Medicine has asked the authors of a major Vioxx study to submit a correction restating results after the journal concluded that cardiovascular events were misrepresented in the study manuscript and that Merck had known about additional events prior to the trial's publication
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.